Lonza Group AG (LZAGF)
USD 740.0
(3.79%)
USD 740.0
(3.79%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.13 Billion CHF | 21.07% |
| 2022 | 2.58 Billion CHF | -5.89% |
| 2021 | 2.74 Billion CHF | -27.92% |
| 2020 | 3.81 Billion CHF | 0.79% |
| 2019 | 3.78 Billion CHF | -6.84% |
| 2018 | 4.06 Billion CHF | -4.33% |
| 2017 | 4.24 Billion CHF | 128.28% |
| 2016 | 1.86 Billion CHF | -4.02% |
| 2015 | 1.93 Billion CHF | -12.74% |
| 2014 | 2.22 Billion CHF | -10.48% |
| 2013 | 2.48 Billion CHF | -11.87% |
| 2012 | 2.81 Billion CHF | -3.96% |
| 2011 | 2.93 Billion CHF | 100.75% |
| 2010 | 1.46 Billion CHF | -2.28% |
| 2009 | 1.49 Billion CHF | -12.78% |
| 2008 | 1.71 Billion CHF | 0.0% |
| 2007 | 1.71 Billion CHF | 48.31% |
| 2006 | 1.15 Billion CHF | -28.97% |
| 2005 | 1.62 Billion CHF | 49.45% |
| 2004 | 1.08 Billion CHF | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 3.79 Billion CHF | 0.0% |
| 2024 Q1 | 3.79 Billion CHF | 21.17% |
| 2023 Q4 | 3.13 Billion CHF | 1.16% |
| 2023 Q1 | 2.91 Billion CHF | 12.49% |
| 2023 FY | 3.13 Billion CHF | 21.07% |
| 2023 Q3 | 3.09 Billion CHF | 6.39% |
| 2023 Q2 | 2.91 Billion CHF | 0.0% |
| 2022 Q2 | 2.4 Billion CHF | 0.0% |
| 2022 Q4 | 2.58 Billion CHF | 2.13% |
| 2022 FY | 2.58 Billion CHF | -5.89% |
| 2022 Q1 | 2.4 Billion CHF | -12.59% |
| 2022 Q3 | 2.53 Billion CHF | 5.41% |
| 2021 FY | 2.74 Billion CHF | -27.92% |
| 2021 Q3 | 2.69 Billion CHF | -25.99% |
| 2021 Q2 | 3.64 Billion CHF | 0.0% |
| 2021 Q1 | 3.64 Billion CHF | -4.38% |
| 2021 Q4 | 2.74 Billion CHF | 1.85% |
| 2020 Q3 | 3.79 Billion CHF | -0.68% |
| 2020 Q2 | 3.81 Billion CHF | 0.0% |
| 2020 Q4 | 3.81 Billion CHF | 0.63% |
| 2020 Q1 | 3.81 Billion CHF | 0.85% |
| 2020 FY | 3.81 Billion CHF | 0.79% |
| 2019 Q1 | 3.78 Billion CHF | -6.84% |
| 2019 Q3 | 3.86 Billion CHF | 2.14% |
| 2019 FY | 3.78 Billion CHF | -6.84% |
| 2019 Q2 | 3.78 Billion CHF | 0.0% |
| 2019 Q4 | 3.78 Billion CHF | -2.1% |
| 2018 Q3 | 4.12 Billion CHF | -2.32% |
| 2018 Q1 | 4.21 Billion CHF | -0.64% |
| 2018 Q4 | 4.06 Billion CHF | -1.43% |
| 2018 FY | 4.06 Billion CHF | -4.33% |
| 2018 Q2 | 4.21 Billion CHF | 0.0% |
| 2017 Q4 | 4.24 Billion CHF | -1.83% |
| 2017 FY | 4.24 Billion CHF | 128.28% |
| 2017 Q2 | 1.71 Billion CHF | 0.0% |
| 2017 Q1 | 1.71 Billion CHF | -7.74% |
| 2017 Q3 | 4.32 Billion CHF | 152.04% |
| 2016 Q3 | 1.91 Billion CHF | 8.74% |
| 2016 Q1 | 1.76 Billion CHF | -9.03% |
| 2016 FY | 1.86 Billion CHF | -4.02% |
| 2016 Q2 | 1.76 Billion CHF | 0.0% |
| 2016 Q4 | 1.86 Billion CHF | -2.97% |
| 2015 Q1 | 2.06 Billion CHF | -6.93% |
| 2015 Q4 | 1.93 Billion CHF | -2.47% |
| 2015 Q2 | 2.06 Billion CHF | 0.0% |
| 2015 Q3 | 1.98 Billion CHF | -3.87% |
| 2015 FY | 1.93 Billion CHF | -12.74% |
| 2014 FY | 2.22 Billion CHF | -10.48% |
| 2014 Q1 | 2.46 Billion CHF | -0.85% |
| 2014 Q2 | 2.46 Billion CHF | 0.0% |
| 2014 Q3 | 2.29 Billion CHF | -6.67% |
| 2014 Q4 | 2.22 Billion CHF | -3.27% |
| 2013 Q4 | 2.48 Billion CHF | -1.63% |
| 2013 FY | 2.48 Billion CHF | -11.87% |
| 2013 Q3 | 2.52 Billion CHF | -9.61% |
| 2013 Q2 | 2.79 Billion CHF | 0.0% |
| 2013 Q1 | 2.79 Billion CHF | -0.89% |
| 2012 Q2 | 2.88 Billion CHF | 0.0% |
| 2012 FY | 2.81 Billion CHF | -3.96% |
| 2012 Q4 | 2.81 Billion CHF | 0.0% |
| 2011 FY | 2.93 Billion CHF | 100.75% |
| 2011 Q4 | 2.93 Billion CHF | 0.0% |
| 2011 Q2 | 1.39 Billion CHF | 0.0% |
| 2010 Q4 | 1.46 Billion CHF | 0.0% |
| 2010 Q2 | 1.41 Billion CHF | 0.0% |
| 2010 FY | 1.46 Billion CHF | -2.28% |
| 2009 Q4 | 1.49 Billion CHF | 0.0% |
| 2009 FY | 1.49 Billion CHF | -12.78% |
| 2009 Q2 | - CHF | 0.0% |
| 2008 Q4 | 1.71 Billion CHF | 0.0% |
| 2008 FY | 1.71 Billion CHF | 0.0% |
| 2007 FY | 1.71 Billion CHF | 48.31% |
| 2006 FY | 1.15 Billion CHF | -28.97% |
| 2005 FY | 1.62 Billion CHF | 49.45% |
| 2004 FY | 1.08 Billion CHF | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.24 Million USD | -139721.429% |
| Arrayit Corporation | 1.07 Million USD | -290393.031% |
| Atlantic International Corp. | 2.93 Million USD | -106776.434% |
| Biocept, Inc. | 12.1 Million USD | -25765.059% |
| Bioqual, Inc. | 3.58 Million USD | -87215.67% |
| CardioGenics Holdings Inc | 72.61 Thousand USD | -4313117.837% |
| DermTech, Inc. | 54.39 Million USD | -5657.988% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 471.86 Million USD | -563.744% |
| HTG Molecular Diagnostics, Inc. | 4.83 Million USD | -64691.76% |
| iMD Companies, Inc. | 1.12 Million USD | -279505.66% |
| IDenta Corp. | 789.14 Thousand USD | -396784.734% |
| Interpace Biosciences, Inc. | 11.19 Million USD | -27884.274% |
| Integrative Health Technologies, Inc. | - USD | -Infinity% |
| InVitro International | 43.84 Thousand USD | -7143245.878% |
| Lumos Diagnostics Holdings Limited | 8.04 Million USD | -38831.429% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 3.82 Million USD | -81763.305% |
| NovelStem International Corp. | 3.57 Million USD | -87518.22% |
| Optigenex Inc. | 8.94 Million USD | -34930.673% |
| PharmChem, Inc. | 77.35 Thousand USD | -4048870.305% |
| Proteome Sciences plc | 17.15 Million USD | -18158.478% |
| Response Genetics, Inc | 6.37 Million USD | -49044.83% |
| Rennova Health, Inc. | 15.32 Million USD | -20331.399% |
| RushNet, Inc. | 4.82 Million USD | -64837.488% |
| ScreenPro Security Inc. | 207.03 Thousand USD | -1512695.0% |
| Stella Diagnostics Inc. | 6.2 Million USD | -50410.548% |
| StageZero Life Sciences Ltd. | 1.8 Million USD | -173891.977% |
| Todos Medical Ltd. | 38.34 Million USD | -8067.31% |